Key secondary clinical endpoints were also positive. Interim data out of this scholarly research will be presented in a poster program at the ASN annual interacting with on Friday, November 19 at 10:00 a.m. MST. In both scholarly studies, interim results were reported at the last captured timepoint. Eculizumab were well-tolerated in the scholarly research, with the most common adverse events including anemia, diarrhea, headaches, nausea and hypertension.. Alexion announces results of eculizumab two open-label Phase 2 studies for aHUS treatment Alexion Pharmaceuticals, Inc. AHUS can be an ultra-rare, persistent and life-threatening disease where uncontrolled complement activation causes bloodstream clots in small arteries through the entire body resulting in stroke, heart assault, kidney failure and death.Safety considerations also required that all of the subjects receive a short 6-week treatment with sibutramine furthermore to advice on way of living modification in order to exclude from randomization subjects who acquired a sensitivity to sibutramine; therefore, the weight changes which were observed in the placebo group after randomization may have resulted from the initial effects of sibutramine instead of from diet and exercise alone. No data on history events in comparable populations that did not receive active weight reduction or preliminary sibutramine treatment are for sale to comparison. Third, to be able to achieve the principal objective of the SCOUT trial, high-risk subjects were selectively recruited; the vast majority didn’t meet the treatment requirements specified on the existing sibutramine label.